Navigation Links
Updated Results from Phase 2 Trial Demonstrate Prolonged Hematologic Relapse-Free Survival of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia
Date:6/14/2010

and uncertainties that could cause actual results to differ materially from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the development of blinatumomab and its use in the treatment of cancer. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that our preclinical data is not confirmed in clinical trials with our product candidates. This factor and others are more fully discussed in our Securities and Exchange Commission filings, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2010.  We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.  We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

References:

1. Nicola Goekbuget, M.D. remarks, Micromet R&D Day, February 2010

2. American Cancer Society. Cancer Facts and Figures 2009.

3. Raff et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment. Blood. 2007109: 910-915


'/>"/>
SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
2. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
3. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
4. Newly Updated Pharmacy State Law Compendium Available
5. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
6. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
7. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
8. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
9. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
10. ORTHO EVRA(R) Prescribing Information Updated
11. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... Conn. , May 27, 2015  With all ... for the services they provide to keep patients healthy ... The ripple effect of the Affordable Care Act continues ... health insurance payer partners, making it more important than ... of communication with those they contract with for patient ...
(Date:5/27/2015)... 2015 The global vitreoretinal surgery ... with analysis and forecast of revenue. This market is ... estimated to grow at a CAGR of 8.9 % ... TOC of the global vitreoretinal surgery devices market report ... This report also provides a glimpse of the market ...
(Date:5/27/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/nt9zlx/asia_pacific ) has announced the ... Growth, Trends And Forecasts (2014 - 2019)" company ... detailed type of imaging that customs a low-dose x-ray ... mammogram, is used to support in the early detection ... (radiograph) is a noninvasive medical test that helps physicians ...
Breaking Medicine Technology:Physicians Seek Payer Inclusion, Not Impediment 2Physicians Seek Payer Inclusion, Not Impediment 3Vitreoretinal Surgery Devices Market is Expected to Reach $1,017.8 Million by 2019, at a CAGR of 8.9 % From 2014 to 2019 2Vitreoretinal Surgery Devices Market is Expected to Reach $1,017.8 Million by 2019, at a CAGR of 8.9 % From 2014 to 2019 3Asia Pacific Mammography Market Trends and Forecasts 2015-2019 2
... NEW YORK, Oct. 27 Intercept Pharmaceuticals, Inc., today ... double-blind Phase II clinical trial of INT-747 in ... evaluated the effects of adding one of three doses ... in patients who did not respond adequately to UDCA ...
... Pharmaceuticals, Inc. today announced $4.5 million in Series A and ... complete the company,s ongoing Phase I/IIa trial of BP-GMAX-CD1 in ... for Phase IIb trials. The company anticipates reporting initial results ... new funding brings the total raised to date to $8.5 ...
Cached Medicine Technology:Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis 2Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis 3Bellicum Pharmaceuticals Announces $4.5 Million in New Funding 2
(Date:5/27/2015)... 2015 While hair transplantation has been ... new pilot study conducted by a physician member of ... found hair follicle grafting can help treat patients with ... funded by ISHRS, which offers research grants for the ... , In the past decade, numerous scientific studies ...
(Date:5/27/2015)... May 27, 2015 The new ... include: Why investors should consider oil and gas investing, ... why wells are drilled, industry news, IRA investing, definitions ... 32 years of knowledge and experience is now in ... community to be able to access 24 hours a ...
(Date:5/27/2015)... CURE® Magazine and the ... to advance research, provide information and support, and raise ... the fifth most common type of cancer, which begins ... grow out of control. , “CURE Magazine provides ... of the cancer experience through digital and print publications, ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 Difass USA, ... in the U.S. with its first three flagship products, ... for purchase nationwide through http://www.difassusa.com . , ... health and productivity, but some people struggle with getting ... Dormiva™ is a sleep aid designed to help you ...
(Date:5/27/2015)... Cincinnati, Ohio (PRWEB) May 27, 2015 Cincinnati ... Education & Research for Veterans (CERV) Foundation is proud to ... information fair for women Veterans June 11 at the Freedom ... Reporter Karin Johnson will be the emcee. , This ... and devotion to the nation. The banquet is free ...
Breaking Medicine News(10 mins):Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 2Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 3Health News:Carson Energy Launches Next Generation Investor Website 2Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 2Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 3Health News:Supplement Brand Difass USA Launches in the U.S. with Three Flagship Products Designed to Bring Balance Back to Your Life 2Health News:Cincinnati VA Women’s Health Clinic Celebrates Women Veterans at Awards Banquet 2
... it eased shoulder pain caused by osteoarthritis , , THURSDAY, Nov. ... pain in arthritis sufferers, a preliminary study found. , "We ... definitive study," said study author Dr. Jasvinder Singh, a staff ... study was small, and more patients needed to be assessed ...
... have discovered that a molecular switch in the protein making ... common forms of lethal breast cancer worldwide. The discovery by ... therapies for the cancer, called locally advanced breast cancer (LABC)., ... LABC may account for 50 percent or more of breast ...
... out of 250 nationwide in annual ,America,s Best,Health Plans, issue, ... ranking of health plans placed Kaiser Permanente of Georgia first ... 250 plans ranked,nationally., The magazine, on newsstands Nov. 5, ... plans -- making it the top,Medicare plan in the state ...
... Pressure,BioSciences, Inc. (Nasdaq: PBIO ) today announced that ... quarter financial results and to,provide a business update. Anyone ... through a live web-cast. The,teleconference and web-cast information is ... Time: 4:30 p.m. Eastern Standard Time (EST) To ...
... Gregory, the Washington,state man who,s spent more than a year ... expects to conclude his odyssey,today at the southernmost city in ... 2006, Gregory set out from his home near the Canadian,border ... his job,with a beverage distributor to accommodate his plans. His ...
... SEATTLE, Nov. 8 Adaptis, a business ... its majority-owned,company, Tela Sourcing, Inc., has purchased ... onshore mailroom, scanning, EDI and PPO routing,services ... Provider,Organizations (PPOs). (Logo: http://www.newscom.com/cgi-bin/prnh/20050113/SFTH042LOGO ) ...
Cached Medicine News:Health News:Botox Offers Shot in Arm for Arthritis Sufferers 2Health News:A molecular switch is linked to a common breast cancer 2Health News:U.S. News & World Report Names Kaiser Permanente Top-Ranked Health Plan in Georgia 2Health News:Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update 2Health News:Cross-Country Walker to Finish His Journey for Cancer Research 2Health News:Tela Sourcing, Inc., an Adaptis Company, Acquires HealthASPex Business 2
... Aestiva Excellence for the Induction Room., ... for the Induction Room. The Aestiva/5 Induction ... anesthesia systems, which helps make it easier ... enhanced features include pneumatic gas mixing, O2 ...
... excellence and economy., ,The Aestiva/5 Compact ... basic ventilation at a moderate price. While ... Aestiva/5 Anesthesia System - open architecture, integrated ... a configurable version of Datex-Ohmeda's newest ventilation ...
... patient care., ,S/5 Anesthesia Delivery Unit ... delivery. As part of the S/5 Anesthesia ... controlled gas delivery and agent vaporization with ... a truly integrated system. The S/5 ADUs ...
A non-adhering hydrogel sheet dressing for use on all partial and full thickness wounds (excluding 3rd degree burns.) Hydrogel sheet contains 96% water and 4% insoluble cross-linked polyethylene oxid...
Medicine Products: